Last Close
Feb 26  •  11:18AM ET
11.00
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-0.93 Insider Own5.03% Shs Outstand34.25M Perf Week1.48%
Market Cap377.85M Forward P/E- EPS next Y-1.07 Insider Trans- Shs Float32.63M Perf Month-12.35%
Enterprise Value189.94M PEG- EPS next Q-0.28 Inst Own93.69% Short Float6.41% Perf Quarter-15.84%
Income-38.96M P/S- EPS this Y-8.10% Inst Trans16.61% Short Ratio11.36 Perf Half Y-13.79%
Sales0.00M P/B2.01 EPS next Y5.37% ROA-28.89% Short Interest2.09M Perf YTD-18.34%
Book/sh5.47 P/C2.00 EPS next 5Y5.01% ROE-29.59% 52W High17.15 -35.86% Perf Year2.23%
Cash/sh5.50 P/FCF- EPS past 3/5Y69.76% 62.31% ROIC-20.74% 52W Low9.85 11.68% Perf 3Y131.18%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.14% 6.41% Perf 5Y-79.46%
Dividend TTM- EV/Sales- EPS Y/Y TTM68.74% Oper. Margin- ATR (14)0.73 Perf 10Y-97.25%
Dividend Ex-Date- Quick Ratio67.69 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)43.40 Recom1.17
Dividend Gr. 3/5Y- - Current Ratio67.69 EPS Q/Q22.74% SMA20-3.98% Beta0.29 Target Price25.20
Payout- Debt/Eq0.01 Sales Q/Q- SMA50-8.06% Rel Volume0.59 Prev Close11.00
Employees19 LT Debt/Eq0.00 EarningsFeb 12 BMO SMA200-16.80% Avg Volume184.11K Price11.00
IPOJun 23, 2014 Option/ShortYes / Yes EPS/Sales Surpr.-16.44% - Trades Volume33,837 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jul-07-25Initiated TD Cowen Buy
Dec-16-24Initiated H.C. Wainwright Buy $28
Dec-13-24Initiated Robert W. Baird Outperform $30
Oct-16-24Initiated Oppenheimer Outperform $35
Sep-12-24Initiated Guggenheim Buy $17
Jul-22-24Initiated Leerink Partners Outperform $13
Jun-13-24Initiated Piper Sandler Overweight $30
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Feb-23-26 07:00AM
Feb-12-26 08:30AM
Jan-11-26 08:00AM
Dec-24-25 09:55AM
Dec-05-25 09:55AM
09:35AM Loading…
Dec-03-25 09:35AM
Nov-18-25 06:16AM
Nov-14-25 05:00PM
Nov-12-25 09:45AM
Nov-06-25 12:19AM
Nov-05-25 04:43PM
Nov-03-25 07:10AM
07:00AM
Nov-02-25 07:00PM
Sep-22-25 04:05PM
08:00AM Loading…
Jul-09-25 08:00AM
Jun-20-25 09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
Jun-16-25 08:50AM
Jun-05-25 09:55AM
Jun-04-25 09:40AM
May-29-25 08:50AM
May-20-25 09:55AM
09:40AM Loading…
May-19-25 09:40AM
May-14-25 07:00AM
May-05-25 08:50AM
May-02-25 09:40AM
Apr-30-25 10:17AM
Apr-25-25 09:55AM
Apr-23-25 12:00PM
Apr-16-25 09:40AM
Apr-15-25 11:51PM
Mar-28-25 09:00AM
Mar-25-25 08:00AM
Mar-19-25 07:00AM
Feb-26-25 07:00AM
Feb-20-25 09:55AM
Feb-14-25 08:10AM
08:00AM
Jan-27-25 08:00AM
Jan-13-25 09:49AM
Dec-17-24 06:25AM
Dec-09-24 09:55AM
08:50AM
Nov-26-24 07:00AM
Nov-14-24 04:30PM
Nov-04-24 08:00AM
Oct-25-24 05:01PM
Oct-14-24 06:00AM
Oct-12-24 06:30AM
Sep-30-24 09:03PM
Sep-26-24 04:30PM
Sep-18-24 08:00AM
Sep-17-24 08:00AM
Jul-15-24 06:00AM
Jul-01-24 07:00AM
May-13-24 02:53PM
08:15AM
May-01-24 08:00AM
Apr-18-24 07:30AM
07:00AM
Apr-09-24 08:00AM
Mar-24-24 07:55AM
Feb-13-24 08:00AM
Nov-30-23 07:00AM
Nov-17-23 08:00AM
Nov-13-23 08:00AM
Sep-21-23 08:00AM
Aug-21-23 09:02PM
Aug-18-23 09:02PM
Aug-11-23 01:00PM
Aug-08-23 10:30PM
Jul-25-23 01:00PM
Jun-26-23 08:00AM
May-15-23 08:00AM
May-08-23 08:05AM
08:00AM
Feb-13-23 08:00AM
Jan-23-23 09:48AM
Nov-10-22 08:00AM
Sep-16-22 08:42AM
Sep-12-22 10:06PM
Sep-02-22 08:00AM
Jul-15-22 06:52AM
May-16-22 08:15AM
Feb-14-22 08:00AM
Jan-18-22 12:53PM
Jan-17-22 09:30AM
Nov-27-21 06:54AM
Nov-15-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 03:58PM
Sep-08-21 08:10AM
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 29 '25Buy13.4477,3871,040,0819,700,195Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 23 '25Buy12.8550,000642,5009,620,075Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 26 '25Buy13.1016,836220,5529,634,395Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 22 '25Buy12.0819,542236,0679,577,475Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 19 '25Buy11.4816,384188,0889,560,825Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 18 '25Buy11.2410,215114,8179,546,875Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorNov 07 '25Buy13.501,481,48119,999,9949,538,175Nov 10 09:51 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorMar 31 '25Buy12.8316,497211,7368,807,805Apr 02 04:37 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorMar 26 '25Buy13.00900,00011,700,0008,793,245Mar 28 04:51 PM
BUCHI J KEVINDirectorFeb 27 '25Option Exercise3.8651,813199,998103,910Mar 03 02:20 PM